Related Experiment Video
Updated: Jun 21, 2026
06:15
Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish
Published on: August 16, 2024
Amiodarone-induced thyrotoxicosis: a review.
1University of Toronto, Toronto, Ontario.
The Canadian Journal of Cardiology
|July 9, 2009
Summary
Amiodarone-induced thyrotoxicosis (AIT) has two types: Type 1, linked to existing thyroid issues, and Type 2, caused by thyroid inflammation. Differentiating and treating these AIT types is crucial for patient outcomes.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Amiodarone-induced thyrotoxicosis (AIT) affects 3% of patients on amiodarone.
- AIT is categorized into Type 1 (pre-existing thyroid pathology) and Type 2 (amiodarone-induced subacute thyroiditis).
Purpose of the Study:
- To review literature on differentiating and managing Type 1 and Type 2 AIT.
- To provide an overview of current diagnostic and therapeutic strategies for AIT.
Main Methods:
- Comprehensive literature search of PubMed, CINAHL, and Medscape (1983-2006).
- Utilized search terms including 'amiodarone-induced thyrotoxicosis', 'management', and 'Doppler sonography'.
Main Results:
- Differentiating AIT types requires history, physical exam, iodine-131 uptake tests, and color flow Doppler sonography.
- Type 2 AIT management involves glucocorticoids; Type 1 AIT requires antithyroid therapy.
- Unclear AIT mechanisms may benefit from combined prednisone and antithyroid treatment.
Conclusions:
- Accurate differentiation of AIT types is essential for appropriate treatment selection.
- Glucocorticoids and antithyroid drugs are primary therapies based on AIT type.
- Further research may refine diagnostic and management protocols for amiodarone-induced thyrotoxicosis.
Related Concept Videos
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:27Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
01:25Hyperthyroidism I: Introduction
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:20Synthesis and Regulation of Thyroid Hormones
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...